Transitional cell carcinoma of the prostate: Clinicopathologic study of 50 cases

John C. Cheville, Paul A. Dundore, David G. Bostwick, Michael M. Lieber, Kenneth P. Batts, Thomas J. Sebo, George M. Farrow

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

BACKGROUND. This study was performed to identify clinical and histologic features most significant in predicting outcome in patients with transitional cell carcinoma (TCC) of the prostate without invasive bladder carcinoma. METHODS. The histologic and clinical material from 50 patients with prostatic TCC without invasive bladder carcinoma were studied. The tumors were divided into the following locoregional categories: 1) TCC in situ (CIS) of the prostatic urethra; 2) CIS of the prostatic ducts and acini; 3) TCC with stromal invasion; 4) TCC with extraprostatic extension and/or seminal vesicle involvement; and 5) lymph node metastases. The Kaplan-Meier method was used to generate survival distributions for the locoregional categories, and comparison of survival curves was accomplished with the log rank test. RESULTS. The 5-year disease specific survival rate was 52%. The 5-year disease specific survival rates for the locoregional categories were as follows: CIS of the prostatic urethra and prostatic ducts and acini (n = 19), 100%; TCC with stromal invasion (n = 21), 45%; TCC with extraprostatic extension and seminal vesicle involvement (n = 3), 0%; and lymph node metastases (n = 7), 30%. There was a significant difference in disease specific survival when patients with CIS were compared with patients with stromal invasion, extraprostatic extension and seminal vesicle involvement, and lymph node metastases (P = 0.0001). CONCLUSIONS. This study demonstrates that patients with prostatic TCC involving prostatic stroma, extraprostatic tissues, seminal vesicles, and lymph nodes have a significantly poorer 5- year disease specific survival than patients with CIS.

Original languageEnglish (US)
Pages (from-to)703-707
Number of pages5
JournalCancer
Volume82
Issue number4
DOIs
StatePublished - Feb 15 1998

Fingerprint

Transitional Cell Carcinoma
Prostate
Seminal Vesicles
Lymph Nodes
Survival
Urethra
Neoplasm Metastasis
Urinary Bladder
Survival Rate
Carcinoma
Carcinoma in Situ

Keywords

  • Bladder neoplasms
  • Pathology
  • Prostate
  • Prostatic neoplasms
  • Transitional cell carcinoma
  • Urothelium

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cheville, J. C., Dundore, P. A., Bostwick, D. G., Lieber, M. M., Batts, K. P., Sebo, T. J., & Farrow, G. M. (1998). Transitional cell carcinoma of the prostate: Clinicopathologic study of 50 cases. Cancer, 82(4), 703-707. https://doi.org/10.1002/(SICI)1097-0142(19980215)82:4<703::AID-CNCR13>3.0.CO;2-1

Transitional cell carcinoma of the prostate : Clinicopathologic study of 50 cases. / Cheville, John C.; Dundore, Paul A.; Bostwick, David G.; Lieber, Michael M.; Batts, Kenneth P.; Sebo, Thomas J.; Farrow, George M.

In: Cancer, Vol. 82, No. 4, 15.02.1998, p. 703-707.

Research output: Contribution to journalArticle

Cheville, JC, Dundore, PA, Bostwick, DG, Lieber, MM, Batts, KP, Sebo, TJ & Farrow, GM 1998, 'Transitional cell carcinoma of the prostate: Clinicopathologic study of 50 cases', Cancer, vol. 82, no. 4, pp. 703-707. https://doi.org/10.1002/(SICI)1097-0142(19980215)82:4<703::AID-CNCR13>3.0.CO;2-1
Cheville, John C. ; Dundore, Paul A. ; Bostwick, David G. ; Lieber, Michael M. ; Batts, Kenneth P. ; Sebo, Thomas J. ; Farrow, George M. / Transitional cell carcinoma of the prostate : Clinicopathologic study of 50 cases. In: Cancer. 1998 ; Vol. 82, No. 4. pp. 703-707.
@article{775c3b4da0b745c784650cc6a052b28d,
title = "Transitional cell carcinoma of the prostate: Clinicopathologic study of 50 cases",
abstract = "BACKGROUND. This study was performed to identify clinical and histologic features most significant in predicting outcome in patients with transitional cell carcinoma (TCC) of the prostate without invasive bladder carcinoma. METHODS. The histologic and clinical material from 50 patients with prostatic TCC without invasive bladder carcinoma were studied. The tumors were divided into the following locoregional categories: 1) TCC in situ (CIS) of the prostatic urethra; 2) CIS of the prostatic ducts and acini; 3) TCC with stromal invasion; 4) TCC with extraprostatic extension and/or seminal vesicle involvement; and 5) lymph node metastases. The Kaplan-Meier method was used to generate survival distributions for the locoregional categories, and comparison of survival curves was accomplished with the log rank test. RESULTS. The 5-year disease specific survival rate was 52{\%}. The 5-year disease specific survival rates for the locoregional categories were as follows: CIS of the prostatic urethra and prostatic ducts and acini (n = 19), 100{\%}; TCC with stromal invasion (n = 21), 45{\%}; TCC with extraprostatic extension and seminal vesicle involvement (n = 3), 0{\%}; and lymph node metastases (n = 7), 30{\%}. There was a significant difference in disease specific survival when patients with CIS were compared with patients with stromal invasion, extraprostatic extension and seminal vesicle involvement, and lymph node metastases (P = 0.0001). CONCLUSIONS. This study demonstrates that patients with prostatic TCC involving prostatic stroma, extraprostatic tissues, seminal vesicles, and lymph nodes have a significantly poorer 5- year disease specific survival than patients with CIS.",
keywords = "Bladder neoplasms, Pathology, Prostate, Prostatic neoplasms, Transitional cell carcinoma, Urothelium",
author = "Cheville, {John C.} and Dundore, {Paul A.} and Bostwick, {David G.} and Lieber, {Michael M.} and Batts, {Kenneth P.} and Sebo, {Thomas J.} and Farrow, {George M.}",
year = "1998",
month = "2",
day = "15",
doi = "10.1002/(SICI)1097-0142(19980215)82:4<703::AID-CNCR13>3.0.CO;2-1",
language = "English (US)",
volume = "82",
pages = "703--707",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Transitional cell carcinoma of the prostate

T2 - Clinicopathologic study of 50 cases

AU - Cheville, John C.

AU - Dundore, Paul A.

AU - Bostwick, David G.

AU - Lieber, Michael M.

AU - Batts, Kenneth P.

AU - Sebo, Thomas J.

AU - Farrow, George M.

PY - 1998/2/15

Y1 - 1998/2/15

N2 - BACKGROUND. This study was performed to identify clinical and histologic features most significant in predicting outcome in patients with transitional cell carcinoma (TCC) of the prostate without invasive bladder carcinoma. METHODS. The histologic and clinical material from 50 patients with prostatic TCC without invasive bladder carcinoma were studied. The tumors were divided into the following locoregional categories: 1) TCC in situ (CIS) of the prostatic urethra; 2) CIS of the prostatic ducts and acini; 3) TCC with stromal invasion; 4) TCC with extraprostatic extension and/or seminal vesicle involvement; and 5) lymph node metastases. The Kaplan-Meier method was used to generate survival distributions for the locoregional categories, and comparison of survival curves was accomplished with the log rank test. RESULTS. The 5-year disease specific survival rate was 52%. The 5-year disease specific survival rates for the locoregional categories were as follows: CIS of the prostatic urethra and prostatic ducts and acini (n = 19), 100%; TCC with stromal invasion (n = 21), 45%; TCC with extraprostatic extension and seminal vesicle involvement (n = 3), 0%; and lymph node metastases (n = 7), 30%. There was a significant difference in disease specific survival when patients with CIS were compared with patients with stromal invasion, extraprostatic extension and seminal vesicle involvement, and lymph node metastases (P = 0.0001). CONCLUSIONS. This study demonstrates that patients with prostatic TCC involving prostatic stroma, extraprostatic tissues, seminal vesicles, and lymph nodes have a significantly poorer 5- year disease specific survival than patients with CIS.

AB - BACKGROUND. This study was performed to identify clinical and histologic features most significant in predicting outcome in patients with transitional cell carcinoma (TCC) of the prostate without invasive bladder carcinoma. METHODS. The histologic and clinical material from 50 patients with prostatic TCC without invasive bladder carcinoma were studied. The tumors were divided into the following locoregional categories: 1) TCC in situ (CIS) of the prostatic urethra; 2) CIS of the prostatic ducts and acini; 3) TCC with stromal invasion; 4) TCC with extraprostatic extension and/or seminal vesicle involvement; and 5) lymph node metastases. The Kaplan-Meier method was used to generate survival distributions for the locoregional categories, and comparison of survival curves was accomplished with the log rank test. RESULTS. The 5-year disease specific survival rate was 52%. The 5-year disease specific survival rates for the locoregional categories were as follows: CIS of the prostatic urethra and prostatic ducts and acini (n = 19), 100%; TCC with stromal invasion (n = 21), 45%; TCC with extraprostatic extension and seminal vesicle involvement (n = 3), 0%; and lymph node metastases (n = 7), 30%. There was a significant difference in disease specific survival when patients with CIS were compared with patients with stromal invasion, extraprostatic extension and seminal vesicle involvement, and lymph node metastases (P = 0.0001). CONCLUSIONS. This study demonstrates that patients with prostatic TCC involving prostatic stroma, extraprostatic tissues, seminal vesicles, and lymph nodes have a significantly poorer 5- year disease specific survival than patients with CIS.

KW - Bladder neoplasms

KW - Pathology

KW - Prostate

KW - Prostatic neoplasms

KW - Transitional cell carcinoma

KW - Urothelium

UR - http://www.scopus.com/inward/record.url?scp=0032520186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032520186&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1097-0142(19980215)82:4<703::AID-CNCR13>3.0.CO;2-1

DO - 10.1002/(SICI)1097-0142(19980215)82:4<703::AID-CNCR13>3.0.CO;2-1

M3 - Article

C2 - 9477103

AN - SCOPUS:0032520186

VL - 82

SP - 703

EP - 707

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 4

ER -